Geranyl formate is a rose-like monoterpene ester strongly associated with geranium-type aromatic profiles in the AromaForge archive. Its evidence base is better than identity alone: public sources support clear registry data, repeated occurrence in rose-geranium oils, flavour-use review, and a grouped toxicology assessment for simple geraniol esters. There is also one rat hepatoprotection paper in the public abstract record, but that finding remains preclinical, dose-sensitive, and too limited to support consumer-facing medical language.
Aroma and practical use
- Use the recorded rose-like, fresh, leafy, green-floral, waxy descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2011 rat study reported partial hepatoprotective effects for low-dose geranyl formate but no hepatoprotective effect at the higher tested dose in a carbon-tetrachloride liver-injury model.
The abstract describes dose-sensitive results and keeps the evidence firmly in a laboratory animal context.
This experimental finding does not establish benefit, dose or safety in people using this blend.
The NICNAS/IMAP assessment states that geranyl formate at 2% produced mild skin irritation in 25 volunteers and was only a slight reversible eye irritant in rabbit data.
The same document says geranyl formate did not cause sensitising effects on guinea pig skin at 20% during the challenge phase in the cited source.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
JECFA maintains a full flavouring specification for geranyl formate and lists it as a colourless to pale yellow liquid with a fresh, leafy, rose-like odour.
This source is especially useful for identity and odor-language grounding rather than for pharmacology.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedThe Australian grouped assessment supports low acute toxicity for geranyl formate and treats the simple geraniol-esters class as generally hydrolyzed after exposure.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
Geranyl formate's most directly verified human observation in this pass was mild irritation at 2% in 25 volunteers, so even though the ingredient is a fragrance/flavouring material, topical claims should stay conservative.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct human clinical efficacy study for isolated geranyl formate was verified in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
expected hydrolysis to geraniol and formic acid
The Australian grouped assessment explicitly treats simple geraniol esters as expected to hydrolyze after exposure; this is still a class-based inference rather than a direct geranyl-formate metabolism paper.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- This pass did not verify a directly readable public RIFM geranyl-formate PDF, even though RIFM assessment metadata are publicly indexed.
- The hepatoprotection paper is a single preclinical signal and is too limited for strong narrative weight.
- No constituent-specific modern dermal maximum for isolated geranyl formate was verified.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.